DBV Technologies SA (DBVT)
13.61
+0.19
(+1.42%)
USD |
NASDAQ |
Sep 02, 16:00
13.61
0.00 (0.00%)
After-Hours: 20:00
DBV Technologies Research and Development Expense (Annual) : 107.12M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 107.12M |
| December 31, 2024 | 89.90M |
| December 31, 2023 | 73.88M |
| December 31, 2022 | 62.58M |
| December 31, 2021 | 69.99M |
| December 31, 2020 | 84.89M |
| December 31, 2019 | 112.22M |
| December 31, 2018 | 123.50M |
| December 31, 2017 | 115.96M |
| Date | Value |
|---|---|
| December 31, 2016 | 85.94M |
| December 31, 2015 | 36.85M |
| December 31, 2014 | 27.43M |
| December 31, 2013 | 22.67M |
| December 31, 2012 | 14.52M |
| December 31, 2011 | 6.878M |
| December 31, 2010 | 6.487M |
| December 31, 2009 | 4.563M |
| December 31, 2008 | 4.484M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Cellectis SA | 75.08M |
| Akari Therapeutics Plc | 2.822M |
| EDAP TMS SA | -- |
| Autolus Therapeutics Plc | 128.59M |
| Evaxion AS | 9.691M |